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Abstract
Mesothelioma is a very rare malignant disease that originates from mesothelial 
cells that line the serosa: pleura, peritoneum, pericardium, or testicular vaginal 
tunic. Peritoneal mesothelioma accounts for 7–10% of all mesotheliomas diag-
nosed, and ranks second after pleural localization of mesothelioma. The incidence 
of peritoneal mesothelioma is 0.5–3 cases per million in men and 0.2–2 cases per 
million in women. Diagnosis of peritoneal mesothelioma is difficult due to non-
specific symptoms and because of this patients present in advanced stages of the 
disease. Histologically there are three major categories of malignant peritoneal 
mesothelioma: epithelioid, sarcomatoid, and biphasic. The differential diagnosis of 
peritoneal mesothelioma is made with peritoneal pseudomyxoma, ovarian tumors, 
and peritoneal metastases from colorectal cancer. An important role in differen-
tial diagnosis, in addition to immunohistochemistry, is played by various tumor 
markers and genetic tests. The treatment of peritoneal mesothelioma is performed 
by cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy 
(HIPEC), with good results for patients in the early stages of the disease. For 
patients with advanced disease, a new treatment has been proposed: pressur-
ized intraperitoneal aerosol chemotherapy (PIPAC). For patients who cannot use 
CRS and HIPEC, the only therapeutic option remains chemotherapy (systemic + 
intraperitoneal).
Keywords: peritoneal mesothelioma, cytoreductive surgery, hyperthermic 
intraperitoneal chemotherapy
1. Introduction
Mesotheliomas arise from cells lining the serosa: pleural, pericardial, peri-
toneal, and testicular vaginal tunic. Mesothelial tumors range from localized 
malignant mesothelioma to aggressive diffuse malignancies that invade the 
anatomical structures of the neighborhood and can give distant metastases. 
Rare mesothelial tumors that represent less than 1% of all diagnosed mesothelial 
tumors are paratesticular mesothelioma and pericardial mesothelioma. The 
peritoneal localization of mesothelioma is on the second place after the pleural 
localization. Peritoneal mesothelioma (PM) is a rare disease with an incidence of 
0.6–3 per million in men and 0.2–2 per million in women [1]. Diffuse malignant 
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peritoneal mesothelioma (DMPM), which accounts for 30% of all malignant 
mesotheliomas, is characterized by symptomatic polymorphism and difficulty in 
establishing a positive diagnosis. In this sense, the immunohistochemical exami-
nation has a very important role in differentiating this disease from peritoneal 
carcinomatosis [2].
2.  Peritoneal mesothelioma: Symptomatology, histopathology, 
differential diagnosis, and treatment
2.1 Symptomatology of PM
The vast majority of patients are asymptomatic. The most common signs appear 
when the tumor mass compresses the neighboring organs or the rupture of cystic 
tumor formations mimicking the symptoms of acute peritonitis, as happened in the 
case operated and treated in our surgery clinic. Thus, the most common symptoms 
are abdominal pain, ascites, anorexia, weight loss, palpable tumor formation, and 
localized or generalized muscle defense [3].
Due to the more frequent localization of peritoneal mesothelioma on the pelvic 
peritoneum, peritoneal adhesions appear on the rectum, uterus, and bladder, 
causing the appearance of other symptoms such as dysuria, urinary symptoms, 
intestinal obstruction, and dyspareunia.
Peritoneal mesothelioma should be differentiated from multicystic peritoneal 
mesothelioma (MCPM) which is a benign, multicystic abdominal tumor such as 
cystic lymphangioma, endometriosis, cystic adenomatoid tumor, pseudomyxoma 
peritonei, and malignant peritoneal mesothelioma. For the positive diagnosis of 
MCPM, it is necessary to perform an immunohistochemical examination [3].
Benign multicystic peritoneal mesothelioma (BMPM) known as multilocular 
peritoneal cysts is an extremely rare disease which has the peritoneal mesothe-
lium as a starting point. Although this disease is considered benign, relapse after 
surgery is reported in over 50% of cases [4] and two cases of malignant transfor-
mation have been reported [5]. Pathogenesis of the disease is unknown. There is a 
discussion of a possible etiopathogenicity related to pelvic inflammatory disease, 
Mediterranean fever, endometriosis, and a history of abdominal surgery. Three 
hypotheses have been proposed in the etiology of BMPM disease. One hypothesis 
argues that BMPM arises from an inflammatory process involving peritoneum, 
which results in hyperplastic and dysplastic reactive transformation of peritoneal 
mesothelial cells. Another theory supports the primary neoplastic origin without 
the involvement of a chronic inflammatory process. Other authors support the 
hormonal theory in which the development and progression of BMPM is closely 
related to sensitivity to sexual hormones. This theory is supported by the fact 
that BMPM has a higher incidence in women during the reproductive period and 
that BMPM responds to tamoxifen and gonadotropin-releasing hormone analogs 
[6]. Most authors agree on the fact that chronic peritoneal inflammatory process 
causes proliferation and migration of peripheral mesothelial cells often associated 
with metaplasia of the underlying connective tissue [6–8]. Transition between 
multicystic mesothelioma and adenomatoid tumor has been observed on several 
occasions [9, 10].
The symptoms of BMPM are insignificant but become apparent when the 
cystic tumors are large enough to produce mass effect on surrounding organs, or if 
the cysts break and produce an acute peritonitis-like reaction, as we have shown. 
Symptoms may be chronic abdominal and/or pelvic pain, abdominal distension, 
intestinal obstruction, and intestinal transit disorders [1, 11–13].
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The physical examination may reveal muscle defense, abdominal distension, or 
acute appendicitis-like symptoms [14].
There are benign or malignant diseases that can mime BMPM. These diseases are 
intestinal lymphangioma and malignant peritoneal mesothelioma. Lymphangioma 
can be diagnosed when the cysts contain predominantly chyli fluid [15] and when 
the presence of lymphoid aggregates, smooth muscle cells, and D2-40-positive 
immunoexpression is discovered in the immunohistochemical examination. 
Malignant peritoneal mesothelioma has a history of asbestos exposure, abdominal 
pain, and weight loss.
2.2 Histopathology of PM
Three histological types of peritoneal mesothelioma have been described: 
epithelioid, sarcomatoid, and biphasic. Patients with sarcomatoid and biphasic 
subtypes have a more reserved prognosis than patients with the epithelioid subtype. 
Multicystic mesothelioma and well-differentiated papillary mesothelioma are forms 
of peritoneal mesothelioma that have a favorable prognosis.
2.2.1 Benign mesothelioma
Benign mesothelioma is a term applied to solitary lesions of peritoneum. Two types 
of benign mesothelial proliferation in the peritoneal cavity are benign multicystic 
peritoneal mesothelioma (MCPM) and adenomatoid tumor.
2.2.2 Malignant mesothelioma
Malignant mesothelioma is commonly found in adults and serum levels of 
osteopontin and mesothelin are serum biomarkers used for diagnosis.
Well-differentiated papillary mesothelioma of peritoneum is multicentric, 
extensive, and is characterized by prominent formation of papillae lined by bland 
mesothelial cell with minimal or no invasion. These are associated with an evolution 
without clinical symptoms, and people with this clinical form of mesothelioma have 
a long survival.
Deciduoid mesothelioma is characterized by the presence of large tumor cells with 
an abundant ground-glass cytoplasm that simulates the appearance of decidual 
cells. This histological form has been described in young women, located not only in 
the pelviperitoneal cavity but also in the pleural cavity in patients of both sexes. It is 
characterized by a short survival.
Mesothelioma with clear cell features can be confused with metastatic carcinoma 
from the kidney. The cytoplasmic clearing is due to the accumulation of glycogen in 
which case the alternative term glycogen-rich mesothelioma has been used.
Malignant mesothelioma with small cell is characterized by the presence of small 
cells. Most of reported cases have been immunoreactive for keratin and mesothelial 
markers including calretinin, CK 5/6, WT1, and podoplanin; some cases also stained 
for neuron-specific enolase and occasionally CD 57.
Lymphohistiocytoid mesothelioma is characterized microscopically by a diffuse 
proliferation of atypical histiocyte-like malignant mesothelial cells admixed with 
numerous lymphocytes (T-cell type) and lesser number of plasma cells. The pheno-
type of the histiocyte-like elements reflects their mesothelial nature and the behavior 
of this tumor is aggressive.
Pleomorphic mesothelioma in the WHO classification scheme is considered a 
variant of epithelioid mesothelioma and is characterized by pleomorphic large 
cells with abundant eosinophilic cytoplasm and single or multiple nuclei with 
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marked variation in size and large nucleoli. The staining for traditional markers 
of mesothelioma-like calretinin, CK 5/6, and WT1 is variable but they are intense 
positive for pankeratin and cytokeratin 7. These tumors are a variant of sarcomatous 
tumors rather than epithelioid mesothelioma, being characterized by an aggressive 
behavior characteristic of sarcomatous tumors.
Desmoplastic mesothelioma is a subtype of sarcomatoid epithelioma, characterized 
by abundant deposition of fibrous tissue demonstrating a storiform arrangement 
of neoplastic spindle cells. The main differential diagnosis is with benign fibrous 
proliferations. Immunohistochemical receptors for keratin, calretinin, and WT1 is in 
favor of desmoplastic mesothelioma.
2.3  Role of immunohistochemistry, electron microscopy, and molecular testing 
in differential diagnosis of mesothelioma
2.3.1 Immunohistochemistry and electron microscopy
The diagnosis of malignant mesothelioma in the absence of detectable invasion 
is problematic in the absence of invasive disease. Homozygous deletion of p16INK4a 
(CDKN2A) detected using a fluorescent in situ hybridization (FISH) assay and loss 
of BAP1 expression by immunohistochemistry may be helpful in separating benign 
from malignant mesothelial proliferations including desmoplastic mesothelioma.
Other immunostains such as epithelial membrane antigen (EMA), p53, GLUT1, 
and IMP3 are proposed for separating benign from malignant mesothelial pro-
liferations. Malignant epithelioid mesotheliomas need to be distinguished from 
metastatic carcinoma, specially adenocarcinomas with pseudo-mesotheliomatous 
growth pattern [3, 16].
The role of immunohistochemistry is in separating sarcomatoid mesotheliomas 
from sarcomatoid carcinomas and soft tissue sarcomas [2]. Mesotheliomas usually 
produce large amounts of hyaluronic acid, which can be demonstrated with the 
alcian blue or colloidal iron stains. The presence of obvious droplets of mucicarmine-
positive or periodic acid-Schiff (PAS)-positive material in the cytoplasm of the 
tumor cell makes the diagnosis of mesothelioma very unlikely, although it does not 
rule it out completely inasmuch as the existence of rare mucin-positive mesothelio-
mas has been demonstrated.
Electron microscopy played an important role in the differential diagnosis 
between mesothelioma and metastatic carcinoma. This was primarily based on 
the appearance of the microvilli in the apical surface of the tumor cells, which in 
mesothelioma are longer and more slender than those in adenocarcinoma.
Many metastatic adenocarcinomas likely to be confused with mesothelioma are 
positive for cytokeratin 7, as are epithelioid mesotheliomas, making cytokeratin 7, as 
are epithelioid mesotheliomas, making cytokeratin 7 and 20 of limited value except 
in very specific context of metastases from the gastrointestinal tract.
The following immunostains are most commonly available and utilized in 
differential diagnosis of mesothelioma:
1. Epithelial markers that are usually present in both tumors (mesothelioma 
and metastatic carcinoma): pankeratins, EMA, and basement membrane 
components;
2. Organ-associated and lineage-specific markers that are often expressed in 
metastatic carcinoma but not mesothelioma: napsin A (lung and kidney), PAX8 
(kidney, mullerian, thymus), CDX2 (gastrointestinal tract, pancreatobiliary), 
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p63/p40 (squamous cell, urothelial), and GATA3 (breast, urothelial,  
squamous cell);
3. Markers that are usually expressed in metastatic carcinoma but not mesothe-
lioma: MOC-31, Ber-EP4, carcinoembryonic antigen (CEA), B72.3, BG8, CD15, 
MUC4, and claudiu-4;
4. Markers that are usually expressed in mesothelioma but not in carcinoma: cal-
retinin (breast, mullerian serous), WT1 (breast, mullerian serous), keratin 5/6 
(urothelial, squamous cell), D2-40/podoplanin (mullerian serous, squamous 
cell), and thrombomodulin (squamous cell).
2.3.2 Molecular genetic features
Mutations in the TP 53 gene are uncommon. In 60–80% of mesothelioma cases, 
homozygous deletion of p16INK4a (CDKN2A) is found, which is an investigation used 
to differentiate benign mesothelial disorders from malignant mesothelial prolifera-
tions. CDKN2A deletion is a potential biomarker for a more aggressive course in 
some cases of mesothelioma. The most common recurrent somatic mutations in 
malignant mesothelioma target three genes functioning as tumor suppressors: 
cyclin-dependent kinase inhibitor 2A (CDKN2A), BCRA1-associated protein 1 
(BAP1), and neurofibromin 2 (merlin) (NF2).
2.3.3 Differential radiological and histopathological diagnosis
Differential diagnosis is made with other peritoneal malignancies such as 
peritoneal pseudomyxoma, ovarian tumors, and peritoneal metastases from 
colorectal cancer. Peritoneal pseudomyxoma is a rare disease characterized by 
multifocal epithelial deposits in the peritoneal cavity, secreted by mucin, with or 
without gelatinous ascites, in the absence of extraperitoneal involvement [17]. It 
was first described by Werth and later by Rokitansky in 1942, being considered 
a fatal condition, with unexplained etiology. It predominates in women, the 
ovarian tumor pathology being incriminated as responsible in a significant per-
centage in the etiopathogenesis of peritoneal pseudomyxoma. In men, adenoma 
(mucocele) appendicular tumors and appendicular adenocarcinoma are the main 
cause described [17]. Virtually any primary solid tumor is the epicenter of the 
malignancy. In the case of peritoneal pseudomixoma, the predominant tumor 
volume is in the peritoneum, and the primary tumor is insignificant, whether it is 
appendicular, ovarian, or in other organs [18]. Pseudomyxoma peritonei involves 
the presence of mucinous, gelatinous deposits in the peritoneum, deposits that can 
reach impressive sizes. Thus, death can be caused by respiratory failure. It seems 
that the basis of this condition is a certain type of mucous cells that have a special 
pattern—the presence of MUC2 [18]. Removal of the tumor and gelatinous material 
is the purpose of treatment.
Peritoneal pseudomixoma is the most serious complication of the appendicular 
mucocele and develops as a result of spontaneous or iatrogenic implantation of 
the tumor into the peritoneal cavity [19]. The peritoneal and occasionally pleural 
pseudomixoma, which appeared as a result of the evolution of the appendicular 
mucocele, is rare and constitutes 6–8.8% [19–21]. Pseudomucinous cysts of the 
ovary, usually associated with appendicular mucocele, are the predominant cause 
of peritoneal pseudomixoma in older women and in men; the origin of peritoneal 
pseudomixoma is usually the vermicular appendix [21]. The pathology has a slow 
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evolution through the loss of intestinal function, fistula formation, and eventual 
death. The most common complications are occlusion and intestinal bleeding.
Extra-abdominal eruption of appendicular cystadenocarcinoma with spontaneous 
cutaneous fistula formation is extremely rare, being published only four cases in the 
world literature [22–25]. The pathogenetic mechanism of spontaneous skin fistula for-
mation in patients with mucinous cystadenocarcinoma of the appendix is enigmatic, 
but we assume that the occurrence of this complication depends on the malignant 
nature of the tumor.
Patients with appendicular mucocele are asymptomatic in about 25% of cases; 
even in the case of large lesions, the most common complaints are pain in the right 
iliac fossa, similar to acute appendicitis and palpable tumor formation in 50% of 
cases [20, 21].
2.4 Treatment
Malignant peritoneal mesothelioma (MPM) is a rare disease with a recur-
rence rate of 40–50% after surgical debulking. Identifying the histological type 
of peritoneal mesothelioma, the number of invaded lymph nodes, and the Ki-67 
proliferation marker are very important parameters for surgical treatment, but 
this is possible in most cases after laparotomy and cytoreductive surgery (CRS). 
The preoperative CT scan, performed by an experienced radiologist, can help us 
identify anatomical sites unfavorable for surgical treatment such as intestinal serosa 
and/or porta hepatis [26].
2.4.1 Cytoreductive surgery (CRS)
For the selection of patients benefiting from CRS, the peritoneal cancer index 
(PCI) is used, which consists of combining a score [27] given by 13 abdomino-
pelvic regions (central, right upper, epigastrium, upper left, left flank, left lower, 
pelvis, right lower, right flank, upper jejunum, lower jejunum, upper ileum, lower 
ileum) to which lesion size score is added (LS 0—no tumor seen; LS 1—tumor up to 
0.5 cm; LS 2—tumor up to 5 cm, and LS 3—tumor >5 cm or confluence).
In MPM, there is an intraoperative extensive invasion at the level of the parietal 
and visceral peritoneum on the surface of the small and large intestines but also in 
the mesentery and mesocolon. Lymph nodes will be removed whenever there is a 
suspicion of invasion, but a complete CRS may require resections of the small and 
large intestines (especially the splenic angle of the colon or the sigmoid colon). 
In order to achieve HIPEC, a complete hemostasis is needed; otherwise, intra-
peritoneal hemorrhage occurs during the procedure. Before HIPEC, an extensive 
intraoperative peritoneal toilet will be performed either with distilled water or 
with diluted hydrogen peroxide (0.25%) or povidone iodine, which aim at the 
mechanical cleansing of possible cancer cells.
Recently, the use of cytoreductive surgery (CRS) in the treatment of peritoneal 
mesothelioma with hyperthermic intraperitoneal chemotherapy (HIPEC) has been 
discussed [28]. Median overall survival for patients with peritoneal mesothelioma 
treated by CRS and HIPEC ranges from 29 to 95 months [29–32].
Research [29] on 405 patients with peritoneal mesothelioma from 29 centers in 
Europe and the US reported that after treatment of peritoneal mesothelioma with 
CRS and HIPEC, a median survival of 53 months and 5-year overall survival rate of 
47%. Overall survival of patients with peritoneal mesothelioma treated with che-
motherapy alone (pemetrexed + cisplatin) was poor (approximately 13 months).
A study [33] of 1514 patients with peritoneal mesothelioma who were 
treated with CRS, CRS and HIPEC, and chemotherapy alone showed a survival 
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of 52 months for CRS, 61 months for CRS and HIPEC, and 17 months after 
chemotherapy.
The reduction of the MPM recurrence rate was obtained by combining CRS 
with HIPEC. The study conducted by Nizri and colleagues [34] on 19 patients with 
MPM who underwent CRS combined with HIPEC showed that after a median 
follow-up of 69 months, all patients were alive and only 4 of the 19 patients had 
recurrences (21%).
2.4.2  Hyperthermic intraperitoneal chemotherapy (HIPEC), early 
postoperative intraperitoneal chemotherapy (EPIC), pressurized 
intraperitoneal aerosol chemotherapy (PIPAC), and normothermic 
intraperitoneal chemotherapy (NIPEC) in treatment of MPM
Additional chemotherapy was used to treat patients with MPM according to 
three therapeutic protocols as follows:
1. HIPEC with doxorubicin and cisplatin
2. Early postoperative intraperitoneal chemotherapy (EPIC) with paclitaxel that 
was added intraperitoneally in the first 5 days after CRS.
3. HIPEC then EPIC and then long-term intraperitoneal paclitaxel or pemetrexed 
intraperitoneally to which cisplatin is added intravenously as an adjunct to 
normothermic intraperitoneal chemotherapy (NIPEC).
In the absence of CRS and HIPEC, the median survival of patients with MPM 
is approximately 1 year. Aggressively applied surgical treatment along with 
additional chemotherapy increased the median survival of patients with MPM 
over 5 years.
The standard recommendations for HIPEC are cisplatin if renal function is good 
(250 mg/m2), cisplatin plus doxorubicin, cisplatin plus mitomycin, or mitomycin 
only. There are also authors who use bidirectional chemotherapy by adding systemic 
ifosfamide plus mesna disulfide by continuing the 90-minute infusion of HIPEC 
with doxorubicin and cisplatin.
Survival in patients with MPM is improved in patients who used CRS plus 
HIPEC compared to patients who used CRS plus hyperthermic perioperative 
chemotherapy.
Recent studies [35] suggest a new therapeutic modality for patients with peri-
toneal mesothelioma: pressurized intraperitoneal aerosol chemotherapy (PIPAC). 
This new therapeutic modality, combined with systemic chemotherapy, may be an 
option for patients to whom CRS and HIPEC cannot be applied.
A retrospective study [36] of 29 patients with peritoneal mesothelioma 
treated with PIPAC (doxorubicin + cisplatin) showed encouraging results. Many 
patients with advanced peritoneal mesothelioma do not benefit from CRS and 
HIPEC, where chemotherapy (systemic + intraperitoneal) remains the only 
therapeutic option.
2.4.3 Molecular therapy and immunotherapy
One hope for molecular therapy in patients with MPM was the identification of 
ALK rearrangements that would be present in 3% of patients with MPM. This has 
been shown to be present in patients <40 years of age who have not been exposed to 
asbestos fibers. It is hoped that these patients will benefit from ALK inhibitors.
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Gefitinib and erlotinib, which are tyrosine kinase inhibitors, acting on the 
epidermal growth factor receptor (EGFR), have been shown to have no significant 
action in MPM. By contrast, angiokinase inhibitors (nintedanib) acting on VEGF 
receptors, platelet-derived-growth factors, fibroblastic growth factors, and Src 
and Abl kinase signaling improved progression-free survival in patients with MPM 
when co-administered with pemetrexed and cisplatin [37].
Bevacizumab, which is an anti-VEGF antibody [38] in combination with cisplatin 
and pemetrexed, significantly increased overall survival in patients with MPM. 
Immune checkpoint inhibitors such as anti-CTLA 4 (tremelimumab and iplimumab) 
and anti-PD1 antibodies (avelumab and durvalumab) are under investigation.
2.4.4 Recommendations in the treatment of MPM
The recommendations discussed at the Washington DC 2016 meeting by the 
Peritoneal Surface Oncology Group International (PSOGI) regarding therapeutic 
strategies [39] in patients with MPM were the following:
1. Patients with MPM who are operable will be given CRS and HIPEC. The applied 
surgical treatment will include peritonectomy procedures (there are still con-
troversies related to parietal peritonectomy: selective parietal peritonectomy 
vs. complete parietal peritonectomy). During the surgical treatment, it will 
be taken into account that the preservation of the viscera is preferred and the 
invaded retroperitoneal lymph nodes will be removed. Optimal cytoreduction 
will be assessed by validated peritoneal staging scoring systems: CC or R-score, 
in which the CRS objectives are to achieve a CC-0 or CC-1 score, in which the 
peritoneal nodules have a diameter of less than 2.5 mm.
HIPEC will be used with cisplatin and carboplatin, either alone or in combina-
tion with doxorubicin, pemetrexed, ifosfamide, and mitomycin. Mitomycin 
has also been used as the only chemotherapeutic agent but with a slight de-
crease in survival. Normothermic intraperitoneal chemotherapy with peme-
trexed and other chemotherapeutic agents has also been used with a slight 
increase in the survival of patients with MPM.
2. Patients with well-differentiated papillary and multicystic mesothelioma will 
be treated with either CRS alone or HIPEC-associated CRS depending on the 
stage of the disease. The benefit of combining HIPEC therapy is unknown.
3. Patients with biphasic, sarcomatoid, or unresectable PMP will only be treated 
by systemic chemotherapy. New chemotherapeutic agents are being tested, 
especially for patients who have seen an increase in Ki67, seen in immunohisto-
chemical studies.
4. The contribution of adjuvant chemotherapy to the treatment of patients with 
PMP is unknown. The study conducted by Sugarbaker and colleagues in 2017 
[27] on long-term adjuvant combined intraperitoneal and systemic chemo-
therapy showed promising results.
It has been shown in published studies that the response rate of malignant 
epithelioid mesothelioma to systemic chemotherapy is around 20%. The 
chemotherapeutic agents used are pemetrexed, carboplatin, cisplatin, and 
bevacizumab.
5. New chemotherapeutic agents such as anti-mesothelin antibody (anetumumab), 
anti-PDL-1 (pembrolizumab), CAR T cells, and Listeria-based immunotherapy 
can improve the survival of patients with PMP.
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There are still no clear recommendations in the follow-up of patients with MPM 
after radical excision surgery [40]. There is a follow-up guide developed by the 
European Society for Medical Oncology for pleural mesothelioma, but no frequency 
or methods of investigation used in the postoperative period (CT, MRI, or ultra-
sonography) are specified. Serum follow-up markers are conventional: CA125 and 
mesothelin.
2.5 Conclusions
Patients with peritoneal mesothelioma, due to nonspecific symptoms, present 
in advanced stages of the disease. An important role in determining the histologi-
cal subtype of peritoneal mesothelioma is played by immunohistochemistry. 
Multidisciplinary management is preferred for patients with MPM. CRS and HIPEC 
appear to be the most effective therapeutic modalities in the treatment of MPM. 
Bidirectional chemotherapy is able to increase the resectability rate in patients with 
diffuse MPM, initially considered unresectable. Modern therapies such as molecular 
therapy and immunotherapy can increase the overall survival of patients with 
MPM. New therapeutic approaches have improved the prognosis only for patients in 
the early stages of the disease.
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